A combination of GamCovidVac and AZD1222 vaccines. Clinical Trials Plan (Phase 1-2)
The trial is small in scale – 100 participants, randomly distributed equally between two groups. Open test – no “blinding” is provided. In one group, the immunization schedule will be AZD1222, then GamCovidVac-Ad26, and in the other, vice versa, GamCovidVac-Ad26 then AZD1222. As you can see, the test scheme is “politically correct”. The subjects will be monitored for adverse events (AEs) and the titers of antibodies binding to protein S (which are not clear, most likely, at least, anti-RBD) and neutralizing antibodies will be determined. In which country this test will be conducted is not specified, but judging by the fact that its main sponsor will be AstraZeneca, it does not have to be Russia.
The first impression is that the work is necessary, but given the speed of replenishment of the vaccine arsenal with proven protective efficacy and the roll-out of mass vaccinations, it is unlikely that the results of this trial will significantly affect the COVID-19 vaccination company, at least in the next year.Поділитися цим: